Literature DB >> 34012668

External validation study of the 8th edition of the American Joint Committee on Cancer staging system for perihilar cholangiocarcinoma: a single-center experience in China and proposal for simplification.

Jian Zhao1,2, Wei Zhang1,2, Jun Zhang1, Wen-Jie Ma3, Si-Yun Liu4, Fu-Yu Li3, Bin Song1.   

Abstract

BACKGROUND: Several changes have been made to the primary tumor (T) and lymph node (N) categories in the new 8th edition of the American Joint Committee on Cancer (AJCC) staging system for perihilar cholangiocarcinoma (pCCA). This study was conducted to validate the 8th edition of the AJCC staging system for pCCA in China.
METHODS: A total of 335 patients who underwent curative-intent resection for pCCA between January 2010 and December 2018 were retrospectively enrolled. The overall survival (OS) of groups of patients was calculated using the Kaplan-Meier method. The log-rank test was used to compare OS between groups. The concordance index (C-index), Akaike information criteria (AIC), and time-dependent area under receiver operating characteristic (ROC) curve (AUC) were computed to evaluate the discriminatory power of the 8th and 7th editions of the AJCC staging system.
RESULTS: The T category changed in 25 (7.5%) patients, the N category changed in 39 (11.6%) patients, and the tumor-node-metastasis (TNM) stage changed in 157 (46.9%) patients when the 8th and 7th editions were compared. No statistically significant difference in survival was observed between T2aN0M0 and T2bN0M0. The C-index of the 8th edition was 0.609 [95% confidence interval (CI): 0.568-0.650], which was slightly higher than that of the 7th edition (C-index, 0.599, 95% CI: 0.558-0.640). The time-dependent AUC value also corroborated that the 8th edition had a better performance than the 7th edition.
CONCLUSIONS: The 8th edition of the AJCC staging system for pCCA showed a better ability than the 7th edition to discriminate patient survival. However, further simplification of the 8th edition is still needed. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  American Joint Committee on Cancer (AJCC); Perihilar cholangiocarcinoma (pCCA); curative-intent resection; overall survival; prognosis

Year:  2021        PMID: 34012668      PMCID: PMC8107634          DOI: 10.21037/jgo-20-348

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  39 in total

1.  Surgical treatment and prognostic analysis of 93 cases of hilar cholangiocarcinoma.

Authors:  Bing-Yuan Zhang; Yun Lu; Qian Dong; Chuan-Dong Sun; Peng Mu
Journal:  Am J Med Sci       Date:  2010-03       Impact factor: 2.378

Review 2.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

3.  Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma.

Authors:  N T E Bird; A McKenna; J Dodd; G Poston; R Jones; H Malik
Journal:  Br J Surg       Date:  2018-07-12       Impact factor: 6.939

4.  Hepatic Artery Resection for Bismuth Type III and IV Hilar Cholangiocarcinoma: Is Reconstruction Always Required?

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-03-06       Impact factor: 3.452

5.  Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.

Authors:  Sarwa Darwish Murad; W Ray Kim; Denise M Harnois; David D Douglas; James Burton; Laura M Kulik; Jean F Botha; Joshua D Mezrich; William C Chapman; Jason J Schwartz; Johnny C Hong; Jean C Emond; Hoonbae Jeon; Charles B Rosen; Gregory J Gores; Julie K Heimbach
Journal:  Gastroenterology       Date:  2012-04-12       Impact factor: 22.682

6.  [Hilar cholangiocarcinoma: The number of positive nodes and positive node/total node ratio is a significant prognostic factor for survival].

Authors:  Gustavo Adrián Nari; Oscar Germán Palacios; Santiago Lopez-Ben; Maite Albiol; Laia Falgueras; Ernesto Castro-Gutierrez; Joan Figueras
Journal:  Cir Esp       Date:  2013-12-04       Impact factor: 1.653

7.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

8.  Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma.

Authors:  Kai Mao; Jieqiong Liu; Jian Sun; Jianlong Zhang; Jie Chen; Timothy M Pawlik; Lisa K Jacobs; Zhiyu Xiao; Jie Wang
Journal:  J Gastroenterol Hepatol       Date:  2016-02       Impact factor: 4.029

Review 9.  Management of perihilar cholangiocarcinoma in the era of multimodal therapy.

Authors:  Vicente Valero; David Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2012-08       Impact factor: 3.869

10.  Survival analysis of patients with stage T2a and T2b perihilar cholangiocarcinoma treated with radical resection.

Authors:  Jian Zhao; Wei Zhang; Jun Zhang; Yi Zhang; Wen-Jie Ma; Si-Yun Liu; Fu-Yu Li; Bin Song
Journal:  BMC Cancer       Date:  2020-09-03       Impact factor: 4.430

View more
  1 in total

1.  Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry.

Authors:  Lynn E Nooijen; Jesus M Banales; Marieke T de Boer; Chiara Braconi; Trine Folseraas; Alejandro Forner; Waclaw Holowko; Frederik J H Hoogwater; Heinz-Josef Klümpen; Bas Groot Koerkamp; Angela Lamarca; Adelaida La Casta; Flora López-López; Laura Izquierdo-Sánchez; Alexander Scheiter; Kirsten Utpatel; Rutger-Jan Swijnenburg; Geert Kazemier; Joris I Erdmann
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.